776 related articles for article (PubMed ID: 23325320)
1. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
Lu B; Palacino J
FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
3. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
4. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
5. Serine 421 regulates mutant huntingtin toxicity and clearance in mice.
Kratter IH; Zahed H; Lau A; Tsvetkov AS; Daub AC; Weiberth KF; Gu X; Saudou F; Humbert S; Yang XW; Osmand A; Steffan JS; Masliah E; Finkbeiner S
J Clin Invest; 2016 Sep; 126(9):3585-97. PubMed ID: 27525439
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
[TBL] [Abstract][Full Text] [Related]
7. Derivation of Huntington's disease-affected human embryonic stem cell lines.
Bradley CK; Scott HA; Chami O; Peura TT; Dumevska B; Schmidt U; Stojanov T
Stem Cells Dev; 2011 Mar; 20(3):495-502. PubMed ID: 20649476
[TBL] [Abstract][Full Text] [Related]
8. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging.
Marcellin D; Abramowski D; Young D; Richter J; Weiss A; Marcel A; Maassen J; Kauffmann M; Bibel M; Shimshek DR; Faull RL; Bates GP; Kuhn RR; Van der Putten PH; Schmid P; Lotz GP
PLoS One; 2012; 7(9):e44457. PubMed ID: 22984513
[TBL] [Abstract][Full Text] [Related]
9. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions.
Davranche A; Aviolat H; Zeder-Lutz G; Busso D; Altschuh D; Trottier Y; Klein FA
Hum Mol Genet; 2011 Jul; 20(14):2795-806. PubMed ID: 21518730
[TBL] [Abstract][Full Text] [Related]
10. Cellular Models: HD Patient-Derived Pluripotent Stem Cells.
Geater C; Hernandez S; Thompson L; Mattis VB
Methods Mol Biol; 2018; 1780():41-73. PubMed ID: 29856014
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
Im W; Ban JJ; Chung JY; Lee ST; Chu K; Kim M
Sci Rep; 2015 Nov; 5():16887. PubMed ID: 26586297
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
Ban JJ; Chung JY; Lee M; Im W; Kim M
Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
[TBL] [Abstract][Full Text] [Related]
13. Meso scale discovery-based assays for the detection of aggregated huntingtin.
Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
[TBL] [Abstract][Full Text] [Related]
14. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
15. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
17. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
Lee CY; Cantle JP; Yang XW
FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
[TBL] [Abstract][Full Text] [Related]
18. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
19. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.
Lu XH; Mattis VB; Wang N; Al-Ramahi I; van den Berg N; Fratantoni SA; Waldvogel H; Greiner E; Osmand A; Elzein K; Xiao J; Dijkstra S; de Pril R; Vinters HV; Faull R; Signer E; Kwak S; Marugan JJ; Botas J; Fischer DF; Svendsen CN; Munoz-Sanjuan I; Yang XW
Sci Transl Med; 2014 Dec; 6(268):268ra178. PubMed ID: 25540325
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]